BACKGROUND INFORMATION ON THE PROCEDURE 
1 
Submission of the dossier 
The applicant Lipomed GmbH submitted on 4 July 2002 an application for Marketing Authorisation to 
the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  through  the  centralised 
procedure  for  LITAK,  which  was  designated  as  an  orphan  medicinal  product  EU/3/01/055  on  18 
September 2001. 
The Rapporteur and Co-Rapporteur appointed by the CPMP  were: 
Rapporteur:  Dr. P. Arlett 
Co-Rapporteur: 
Dr. J. Ersbøll 
Orphan Drugs: 
Cladribine  (subcutaneous  use)  was  designated  as  an  orphan  medicinal  product  for  the  orphan 
indication: Treatment of indolent non-Hodgkin’s lymphoma. 
Licensing status: 
LITAK  has  been  approved  in  Switzerland  (May  2000),  Israel  (January  2001),  Cyprus  (May  2001), 
Romania (December 2001), Bulgaria (February 2001), Slovakia (March 2003), Iran (November 2002), 
Iraq  (May  2002),  Syria  (August  2002)  for  the  treatment  of  indolent  Non-Hodgkin’s  lymphoma,  as 
follows:  as  first  line  treatment  of  hairy  cell  leukaemia,  as  second  line  treatment  in  recurrent  or 
refractory  grade  I  and  II  follicular  lymphoma  and  indolent  disseminated  lymphomas  (chronic 
lymphocytic leukaemia, small lymphocytic leukaemia, lymphoplasmacytic lymphoma).  
In  Europe  cladribine,  intended  to  be  administered  as  an  intravenous  infusion,  was  first  approved  in 
Sweden in November 1993 for the treatment of hairy cell leukaemia. It is now available in all Member 
States of the Community except Ireland. In Austria, Finland, Portugal, Spain and the United Kingdom, 
the approved therapeutic indication also includes certain other lymphoid malignancies. 
2 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 22 July 2002. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
25 September 2002. The Co-Rapporteur's first Assessment Report was circulated to all CPMP 
members on 4 October 2002. 
During  the  meeting  on  19-21  November  2002  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 22 November 2002. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
11 April 2003. 
The (Co)Rapporteur circulated the joint Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 21 May 2003. 
During the CPMP meeting on 24 - 26 June 2003 the CPMP adopted a List of Outstanding Issues 
to be addressed by the applicant in writing and if necessary during an oral explanation. 
The (Co)Rapporteur circulated the joint Assessment Report on the applicant’s responses to the 
List of Outstanding Issues to all CPMP members on 18 September 2003. 
During the CPMP meeting on 23 – 25 September 2003, outstanding issues were addressed by 
the applicant during a hearing before the CPMP on 24 September 2003. 
1/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
During  the  meeting  on  21  –  22  October  2003  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to LITAK on 22 October 2003. 
The European Commission returned the initial CPMP Opinion of October 2003 to the EMEA, 
requesting to reconsider this application according to a different legal basis. 
During  the  meeting  on  20  -  21  January  2004  the  CPMP,  in  the  light  of  the  overall  data  and 
justifications  submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  revised 
positive Opinion for granting a Marketing Authorisation to LITAK on 21 January 2004. 
2/2 
EMEA 2004 
 
 
 
 
 
